EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of novel Kir4.1 inhibitors based on serdemetan with potential therapy for glioblastoma-depression comorbidity

Hao Gu, Sisi Wang, Mengdan Li, Yunpeng Guo, Xiaokang Li, Zhaobing Gao, Jian Li, Hanfang Liu, Xiaoyu Zhou, Yixiang Xu

Pharmaceutical Science Advances · 2026-12 · 4 · 100124

DOI: 10.1016/j.pscia.2026.100124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Hao Gu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Ce…. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Postdoctoral Program for Innovative Talents, Innovative Research Team of High-level Local University in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AntidepressionAntigliomaBifunctional compoundKir4.1 inhibitorsStructural repurposing

Autor:innen und Institutionen

  • State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory…
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528437, China.
  • Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, 832003, China.
  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China.
  • Center for Translational Medicine, Huaihe Hospital of Henan University, Kaifeng, 475004, China.

Förderung

  • National Natural Science Foundation of China
  • National Postdoctoral Program for Innovative Talents
  • Innovative Research Team of High-level Local University in Shanghai
  • State Key Laboratory of Bioreactor Engineering
  • Chinese Academy of Sciences
  • China Postdoctoral Science Foundation

Zitieren

APA

Gu, H., Wang, S., Li, M., Guo, Y., Li, X., Gao, Z., Li, J., Liu, H., Zhou, X., & Xu, Y. (2026). Discovery of novel Kir4.1 inhibitors based on serdemetan with potential therapy for glioblastoma-depression comorbidity. Pharmaceutical Science Advances, 4, 100124. https://doi.org/10.1016/j.pscia.2026.100124

Vancouver

Gu H, Wang S, Li M, Guo Y, Li X, Gao Z, et al. Discovery of novel Kir4.1 inhibitors based on serdemetan with potential therapy for glioblastoma-depression comorbidity. Pharmaceutical Science Advances. 2026;4:100124. doi:10.1016/j.pscia.2026.100124

BibTeX
@article{Gu2026,
  author = {Gu, Hao and Wang, Sisi and Li, Mengdan and Guo, Yunpeng and Li, Xiaokang and Gao, Zhaobing and Li, Jian and Liu, Hanfang and Zhou, Xiaoyu and Xu, Yixiang},
  title = {Discovery of novel Kir4.1 inhibitors based on serdemetan with potential therapy for glioblastoma-depression comorbidity},
  journal = {Pharmaceutical Science Advances},
  year = {2026},
  volume = {4},
  pages = {100124},
  doi = {10.1016/j.pscia.2026.100124}
}
Kostenlos starten →